M&A Deal Summary |
|
|---|---|
| Date | 2024-04-09 |
| Target | Beacon Therapeutics - Chemistry Manufacturing & Controls |
| Sector | Manufacturing |
| Buyer(s) | Ascend |
| Sellers(s) | Beacon Therapeutics |
| Deal Type | Divestiture |
SEARCH BY
Ascend is an adeno-associated virus (AAV) development partner working to bring next-generation gene therapy products to market. Ascend was founded in 2021 and is based in London, England.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Manufacturing M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Florida M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 2023 |
| Sector | Life Science |
Beacon Therapeutics is an ophthalmic gene therapy company that saves and restores the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. Beacon Therapeutics was founded in 2023 and is based in Alachua, Florida.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Manufacturing M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Florida M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
